Mesenchymal stem cells enhance NOX2-dependent reactive oxygen species production and bacterial killing in macrophages during sepsis

European Respiratory Journal

Volumn 51, Issue 4, 2018, Pages

  Rabani, Razieh ^a   Volchuk, Allen ^a   Jerkic, Mirjana ^a   Ormesher, Lindsay ^a   Garces Ramirez, Linda ^a,b   Canton, Johnathan ^c   Masterson, Claire ^a   Gagnon, Stephane ^a   Tatham, Kate C ^a,d   Marshall, John ^a,e   Grinstein, Sergio ^c   Laffey, John G ^a,e,f   Szaszi, Katalin ^a,e   Curley, Gerard F ^a,f,g  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; CYBB PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CLEARANCE; BACTERICIDAL ACTIVITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE FUNCTION; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; OUTCOME ASSESSMENT; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEPSIS; ANIMAL; CELL DIFFERENTIATION; COCULTURE; CYTOLOGY; ESCHERICHIA COLI INFECTION; IMMUNOLOGY; MACROPHAGE ACTIVATION; METABOLISM; MICROBIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CELL DIFFERENTIATION; COCULTURE TECHNIQUES; ESCHERICHIA COLI INFECTIONS; HUMANS; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; MESENCHYMAL STEM CELLS; NADPH OXIDASE 2; PHAGOCYTOSIS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SEPSIS;

EID: 85055060627     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02021-2017     Document Type: Article

References (58)

1. Brun-Buisson C, Meshaka P, Pinton P, et al. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004; 30: 580-588.
2. Liu V, Escobar GJ, Greene JD, et al. Hospital deaths in patients with sepsis from 2 independent cohorts. JAMA 2014; 312: 90-92.
3. Mendez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010; 466: 829-834.
4. Shi C, Jia T, Mendez-Ferrer S, et al. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating Toll-like receptor ligands. Immunity 2011; 34: 590-601.
5. Friedenstein AJ, Petrakova KV, Kurolesova AI, et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968; 6: 230-247.
6. Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008; 3: 301-313.
7. Curley GF, Ansari B, Hayes M, et al. Effects of intratracheal mesenchymal stromal cell therapy during recovery and resolution after ventilator-induced lung injury. Anesthesiology 2013; 118: 924-932.
8. Curley GF, Hayes M, Ansari B, et al. Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat. Thorax 2012; 67: 496-501.
9. Curley GF, Jerkic M, Dixon S, et al. Cryopreserved, xeno-free human umbilical cord mesenchymal stromal cells reduce lung injury severity and bacterial burden in rodent Escherichia coli-induced acute respiratory distress syndrome. Crit Care Med 2017; 45: e202-e212.
10. McIntyre LA, Stewart DJ, Mei SHJ, et al. Cellular immunotherapy for septic shock. A phase I clinical trial. Am J Respir Crit Care Med 2018; 197: 337-347.
11. Liu KD, Wilson JG, Zhuo H, et al. Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. Ann Intensive Care 2014; 4: 22.
12. Ko JH, Lee HJ, Jeong HJ, et al. Mesenchymal stem/stromal cells precondition lung monocytes/macrophages to produce tolerance against allo-and autoimmunity in the eye. Proc Natl Acad Sci USA 2016; 113: 158-163.
13. Vasandan AB, Jahnavi S, Shashank C, et al. Human mesenchymal stem cells program macrophage plasticity by altering their metabolic status via a PGE2-dependent mechanism. Sci Rep 2016; 6: 38308.
14. Nemeth K, Leelahavanichkul A, Yuen PST, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15: 42-49.
15. Canton J, Khezri R, Glogauer M, et al. Contrasting phagosome pH regulation and maturation in human M1 and M2 macrophages. Mol Biol Cell 2014; 25: 3330-3341.
16. Miles SA, Conrad SM, Alves RG, et al. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med 2005; 201: 747-754.
17. Muller U, Stenzel W, Kohler G, et al. IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J Immunol 2007; 179: 5367-5377.
18. Devaney J, Horie S, Masterson C, et al. Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E. coli in the rat. Thorax 2015; 70: 625-635.
19. Krasnodembskaya A, Samarani G, Song Y, et al. Human mesenchymal stem cells reduce mortality and bacteremia in Gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol 2012; 302: L1003-L1013.
20. Mei SH, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010; 182: 1047-1057.
21. O'Croinin DF, Nichol AD, Hopkins N, et al. Sustained hypercapnic acidosis during pulmonary infection increases bacterial load and worsens lung injury. Crit Care Med 2008; 36: 2128-2135.
22. Jackson MV, Morrison TJ, Doherty DF, et al. Mitochondrial transfer via tunneling nanotubes (TNT) is an important mechanism by which mesenchymal stem cells enhance macrophage phagocytosis in the in vitro and in vivo models of ARDS. Stem Cells 2016; 34: 2210-2223.
23. Morrison TJ, Jackson MV, Cunningham EK, et al. Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer. Am J Respir Crit Care Med 2017; 196: 1275-1286.
24. Krasnodembskaya A, Song Y, Fang X, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010; 28: 2229-2238.
25. Gupta N, Krasnodembskaya A, Kapetanaki M, et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax 2012; 67: 533-539.
26. Leto TL, Morand S, Hurt D, et al. Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases. Antioxid Redox Signal 2009; 11: 2607-2619.
27. Nunes P, Demaurex N, Dinauer MC. Regulation of the NADPH oxidase and associated ion fluxes during phagocytosis. Traffic 2013; 14: 1118-1131.
28. Vieira OV, Botelho RJ, Rameh L, et al. Distinct roles of class I and class III phosphatidylinositol 3-kinases in phagosome formation and maturation. J Cell Biol 2001; 155: 19-25.
29. Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 2009; 37: 1445-1453.
30. Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014; 41: 14-20.
31. Roszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm 2015; 2015: 816460.
32. Jaguin M, Houlbert N, Fardel O, et al. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. Cell Immunol 2013; 281: 51-61.
33. Fuentes-Duculan J, Suarez-Farinas M, Zaba LC, et al. A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol 2010; 130: 2412-2422.
34. Melief SM, Schrama E, Brugman MH, et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 2013; 31: 1980-1991.
35. Francois M, Romieu-Mourez R, Li M, et al. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 2012; 20: 187-195.
36. McWhorter FY, Wang T, Nguyen P, et al. Modulation of macrophage phenotype by cell shape. Proc Natl Acad Sci USA 2013; 110: 17253-17258.
37. Novais FO, Nguyen BT, Beiting DP, et al. Human classical monocytes control the intracellular stage of Leishmania braziliensis by reactive oxygen species. J Infect Dis 2014; 209: 1288-1296.
38. Novais FO, Santiago RC, Bafica A, et al. Neutrophils and macrophages cooperate in host resistance against Leishmania braziliensis infection. J Immunol 2009; 183: 8088-8098.
39. Lam GY, Huang J, Brumell JH. The many roles of NOX2 NADPH oxidase-derived ROS in immunity. Semin Immunopathol 2010; 32: 415-430.
40. Delano MJ, Ward PA. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J Clin Invest 2016; 126: 23-31.
41. DeLeo FR, Allen LA, Apicella M, et al. NADPH oxidase activation and assembly during phagocytosis. J Immunol 1999; 163: 6732-6740.
42. Ratcliffe MJ, Walding A, Shelton PA, et al. Activation of E-prostanoid4 and E-prostanoid2 receptors inhibits TNF-alpha release from human alveolar macrophages. Eur Respir J 2007; 29: 986-994.
43. Menard G, Turmel V, Bissonnette EY. Serotonin modulates the cytokine network in the lung: involvement of prostaglandin E2. Clin Exp Immunol 2007; 150: 340-348.
44. Kabashima K, Sakata D, Nagamachi M, et al. Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med 2003; 9: 744-749.
45. Yao C, Sakata D, Esaki Y, et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion. Nat Med 2009; 15: 633-640.
46. Kuehn HS, Jung MY, Beaven MA, et al. Prostaglandin E2 activates and utilizes mTORC2 as a central signaling locus for the regulation of mast cell chemotaxis and mediator release. J Biol Chem 2011; 286: 391-402.
47. Sokolowska M, Chen LY, Liu Y, et al. Prostaglandin E2 inhibits NLRP3 inflammasome activation through EP4 receptor and intracellular cyclic AMP in human macrophages. J Immunol 2015; 194: 5472-5487.
48. Hubbard NE, Lee S, Lim D, et al. Differential mRNA expression of prostaglandin receptor subtypes in macrophage activation. Prostaglandins Leukot Essent Fatty Acids 2001; 65: 287-294.
49. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol 2012; 188: 21-28.
50. Ip WK, Sokolovska A, Charriere GM, et al. Phagocytosis and phagosome acidification are required for pathogen processing and MyD88-dependent responses to Staphylococcus aureus. J Immunol 2010; 184: 7071-7081.
51. West AP, Brodsky IE, Rahner C, et al. TLR signaling augments macrophage bactericidal activity through mitochondrial ROS. Nature 2011; 472: 476-480.
52. Phinney DG, Di Giuseppe M, Njah J, et al. Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs. Nat Commun 2015; 6: 8472.
53. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11: 723-737.
54. Mittal M, Tiruppathi C, Nepal S, et al. TNFalpha-stimulated gene-6 (TSG6) activates macrophage phenotype transition to prevent inflammatory lung injury. Proc Natl Acad Sci USA 2016; 113: E8151-E8158.
55. Lee JW, Krasnodembskaya A, McKenna DH, et al. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 2013; 187: 751-760.
56. Monsel A, Zhu YG, Gennai S, et al. Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice. Am J Respir Crit Care Med 2015; 192: 324-336.
57. Galipeau J. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy 2013; 15: 2-8.
58. Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 2015; 17: 11-22.